Mark P Christiansen
Overview
Explore the profile of Mark P Christiansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
McCarthy O, Eckstein M, Scott S, Fontana F, Christiansen M, Stettler C, et al.
BMJ Open Diabetes Res Care
. 2020 Apr;
8(1).
PMID: 32303532
Introduction: This prospective observational study sought to establish the glycemic, physiological and dietary demands of strenuous exercise training as part of a 9-day performance camp in a professional cycling team...
12.
Scott S, Christiansen M, Fontana F, Stettler C, Bracken R, Hayes C, et al.
Diabetes Care
. 2020 Mar;
43(5):1142-1145.
PMID: 32179510
Objective: To investigate factors related to glycemic management among members of a professional cycling team with type 1 diabetes over a 7-day Union Cycliste Internationale World Tour stage race. Research...
13.
Adler S, Lewis N, Conlon A, Christiansen M, Al-Ibrahim M, Rupp R, et al.
J Infect Dis
. 2019 Sep;
220(3):411-419.
PMID: 31535143
Background: A conditionally replication-defective human cytomegalovirus (CMV) vaccine (V160) derived from AD169 and genetically engineered to express CMV pentameric complex (gH/gL/pUL128/pUL130/pUL131) was developed and evaluated for phase 1 vaccine safety...
14.
Christiansen M, Klaff L, Bailey T, Brazg R, Carlson G, Tweden K
Diabetes Technol Ther
. 2019 Mar;
21(5):231-237.
PMID: 30925083
A prior study (PRECISE II) demonstrated that an implantable continuous glucose monitoring (CGM) system (Eversense CGM System) provided accurate glucose readings through the 90-day sensor life with a favorable safety...
15.
Forlenza G, Buckingham B, Christiansen M, Wadwa R, Peyser T, Lee J, et al.
Diabetes Technol Ther
. 2019 Mar;
21(5):265-272.
PMID: 30925077
The objective of this study was to assess the safety and performance of the Omnipod personalized model predictive control (MPC) algorithm with variable glucose setpoints and moderate intensity exercise using...
16.
Buckingham B, Christiansen M, Forlenza G, Wadwa R, Peyser T, Lee J, et al.
Diabetes Technol Ther
. 2018 Aug;
20(9):585-595.
PMID: 30070928
Background: This study assessed the safety and performance of the Omnipod personalized model predictive control (MPC) algorithm using an investigational device in adults with type 1 diabetes in response to...
17.
Slover R, Tryggestad J, DiMeglio L, Fox L, Bode B, Bailey T, et al.
Diabetes Technol Ther
. 2018 Aug;
20(9):576-584.
PMID: 30063162
Background: This study evaluated the safety and performance of the Guardian™ continuous glucose monitoring (CGM) system in children and adolescents with type 1 diabetes (T1D). Materials And Methods: Subjects 2-18...
18.
Buckingham B, Forlenza G, Pinsker J, Christiansen M, Wadwa R, Schneider J, et al.
Diabetes Technol Ther
. 2018 Feb;
20(4):257-262.
PMID: 29431513
Background: The safety and feasibility of the OmniPod personalized model predictive control (MPC) algorithm in adult, adolescent, and pediatric patients with type 1 diabetes were investigated. Methods: This multicenter, observational...
19.
Christiansen M, Klaff L, Brazg R, Chang A, Levy C, Lam D, et al.
Diabetes Technol Ther
. 2018 Jan;
20(3):197-206.
PMID: 29381090
Background: Persistent use of real-time continuous glucose monitoring (CGM) improves diabetes control in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D). Methods: PRECISE II was a nonrandomized,...
20.
Christiansen M, Garg S, Brazg R, Bode B, Bailey T, Slover R, et al.
Diabetes Technol Ther
. 2017 Jul;
19(8):446-456.
PMID: 28700272
Background: This study evaluated the accuracy and performance of a fourth-generation subcutaneous glucose sensor (Guardian Sensor 3) in the abdomen and arm. Methods: Eighty-eight subjects (14-75 years of age, mean ...